<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00027391</url>
  </required_header>
  <id_info>
    <org_study_id>FD-R-2029-01</org_study_id>
    <secondary_id>FD-R-002029-01</secondary_id>
    <nct_id>NCT00027391</nct_id>
  </id_info>
  <brief_title>Study of Albuterol and Oxandrolone in Patients With Facioscapulohumeral Dystrophy (FSHD)</brief_title>
  <official_title>Clinical Trials of Albuterol and Oxandrolone in FSH Dystrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>FDA Office of Orphan Products Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>FDA Office of Orphan Products Development</source>
  <brief_summary>
    <textblock>
      This is a study to determine whether albuterol or oxandrolone, alone or in combination, are&#xD;
      able to increase strength and muscle mass in patients with FSHD. It also will determine if&#xD;
      albuterol given in &quot;pulsed&quot; fashion will have more effect than when given continuously.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be randomized to 1 of 4 groups: placebo, pulsed albuterol, oxandrolone, or both&#xD;
      pulsed albuterol and oxandrolone. Treatment will continue for 52 weeks unless unacceptable&#xD;
      side effects occur. Patients will undergo testing of muscle function. All patients will&#xD;
      return for follow-up assessments at Weeks 4, 12, 26, and 52.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2001</start_date>
  <completion_date>August 2004</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <enrollment>160</enrollment>
  <condition>Muscular Dystrophies</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Albuterol</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxandrolone</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Presence of 4q35 &quot;small fragment&quot; of less than 40 kb by standard DNA testing&#xD;
&#xD;
          -  Weakness of the facial muscles, including frontalis, orbicularis oculi, or orbicularis&#xD;
             oris&#xD;
&#xD;
          -  Weakness of scapular stabilizers or foot dorsiflexors&#xD;
&#xD;
          -  Ambulatory&#xD;
&#xD;
          -  Weakness grade 2 or worse in the arm using upper extremity grading scale&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Prior use of oral beta-2 agonists for a period of at least 1 year or within the past 3&#xD;
             months&#xD;
&#xD;
          -  Concurrent use of other sympathomimetic agents, antidepressants, or beta-2 receptor&#xD;
             blockers&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Known hypersensitivity to anabolic steroids&#xD;
&#xD;
          -  Any medical or psychological condition that would interfere with the study&#xD;
&#xD;
          -  Requirement for a wheelchair&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John T. Kissel, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ohio State University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ohio State University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2001</verification_date>
  <study_first_submitted>December 5, 2001</study_first_submitted>
  <study_first_submitted_qc>December 6, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 7, 2001</study_first_posted>
  <last_update_submitted>March 24, 2015</last_update_submitted>
  <last_update_submitted_qc>March 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 25, 2015</last_update_posted>
  <keyword>Muscle Weakness, Muscular Dystrophy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Dystrophies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Albuterol</mesh_term>
    <mesh_term>Oxandrolone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

